![Richard Giroux](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Richard Giroux
Director of Finance/CFO at
MEIRAGTX HOLDINGS PLC
Net worth: 14 M $ as of 30/06/2026
Profile
Richard Giroux is Chief Operating Officer & Chief Financial Officer at MeiraGTx UK II Ltd. and MeiraGTx Ireland DAC.
Since 2019, Mr. Giroux is Chief Operating & Financial Officer at MeiraGTx Holdings Plc.
Former roles include Independent Director at Chardan Healthcare Acquisition Corp.
from 2018 to 2019, Independent Director at Chardan Healthcare Acquisition 2 Corp., Partner at Sivik Global Healthcare LLC from 2001 to 2008, Partner at Sarissa Capital Management LP from 2014 to 2015, and Partner at Meadowvale Partners Capital Management LLC from 2010 to 2012.
Education includes undergraduate studies at Yale University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 25/06/2026 | 10,54,682 ( 1.14% ) | 14 M $ | 30/06/2026 |
Richard Giroux active positions
| Companies | Position | Start |
|---|---|---|
| MEIRAGTX HOLDINGS PLC | Director of Finance/CFO | 16/04/2019 |
MeiraGTx UK II Ltd.
 MeiraGTx UK II Ltd. Pharmaceuticals: MajorHealth Technology Develops novel gene-based therapies for retinal disorders that lead to vision loss | Director of Finance/CFO | - |
MeiraGTx Ireland DAC | Director of Finance/CFO | - |
Former positions of Richard Giroux
| Companies | Position | End |
|---|---|---|
| CHARDAN HEALTHCARE ACQUISITION CORP | Director/Board Member | 01/10/2019 |
Sarissa Capital Management LP
 Sarissa Capital Management LP Investment ManagersFinance Sarissa seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. They conduct rigorous, fundamentals-based research. Sarissa is an activist firm and is included in SharkWatch50 as one of the 50 most prominent and impactful activist investors. | Corporate Officer/Principal | 01/03/2015 |
Meadowvale Partners Capital Management LLC
 Meadowvale Partners Capital Management LLC Investment ManagersFinance Meadowvale Partners Capital Management manages a multi-manager hedge fund. Portfolios are designed to provide clients' overall portfolios with diversification, low volatility and attractive risk-adjusted returns. | Corporate Officer/Principal | 01/06/2012 |
Sivik Global Healthcare LLC (Old)
 Sivik Global Healthcare LLC (Old) Investment ManagersFinance Sivik invests almost exclusively in US growth stocks in the healthcare technology and services sector without regard to capitalization size. They use a combination top-down, bottom-up approach to find companies with new drugs or technologies and sector dominance or competitive advantages. SIVIK maintains a high turnover | Corporate Officer/Principal | 01/11/2008 |
| RENOVACOR, INC. | Director/Board Member | - |
Training of Richard Giroux
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
14
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Sivik Global Healthcare LLC (Old)
Sivik Global Healthcare LLC (Old) Investment ManagersFinance Sivik invests almost exclusively in US growth stocks in the healthcare technology and services sector without regard to capitalization size. They use a combination top-down, bottom-up approach to find companies with new drugs or technologies and sector dominance or competitive advantages. SIVIK maintains a high turnover | Finance |
Sarissa Capital Management LP
Sarissa Capital Management LP Investment ManagersFinance Sarissa seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. They conduct rigorous, fundamentals-based research. Sarissa is an activist firm and is included in SharkWatch50 as one of the 50 most prominent and impactful activist investors. | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Meadowvale Partners Capital Management LLC
Meadowvale Partners Capital Management LLC Investment ManagersFinance Meadowvale Partners Capital Management manages a multi-manager hedge fund. Portfolios are designed to provide clients' overall portfolios with diversification, low volatility and attractive risk-adjusted returns. | Finance |
MeiraGTx Holdings Plc
 MeiraGTx Holdings Plc BiotechnologyHealth Technology Develops and manufactures genetic medicines | Health Technology |
MeiraGTx UK II Ltd.
MeiraGTx UK II Ltd. Pharmaceuticals: MajorHealth Technology Develops novel gene-based therapies for retinal disorders that lead to vision loss | Health Technology |
Chardan Healthcare Acquisition Corp.
 Chardan Healthcare Acquisition Corp. Financial ConglomeratesFinance Operates as blank check company | Finance |
Chardan Healthcare Acquisition 2 Corp.
 Chardan Healthcare Acquisition 2 Corp. Financial ConglomeratesFinance Operates as blank check company | Finance |
MeiraGTx Ireland DAC |
- Stock Market
- Insiders
- Richard Giroux
Choose MarketScreener 
